BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE Drug Patent Profile
✉ Email this page to a colleague
When do Buprenorphine Hydrochloride And Naloxone Hydrochloride patents expire, and when can generic versions of Buprenorphine Hydrochloride And Naloxone Hydrochloride launch?
Buprenorphine Hydrochloride And Naloxone Hydrochloride is a drug marketed by Alvogen, Difgen Pharms, Dr Reddys Labs Sa, Mylan Technologies, Actavis Elizabeth, Alkem Labs Ltd, Amneal Pharms, Ethypharm Usa Corp, Hikma, Lannett Co Inc, Rhodes Pharms, Specgx Llc, Sun Pharm, Teva Pharms Usa, and Wes Pharma Inc. and is included in eighteen NDAs.
The generic ingredient in BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE is buprenorphine hydrochloride; naloxone hydrochloride. There are twenty-nine drug master file entries for this compound. Twenty-four suppliers are listed for this compound. Additional details are available on the buprenorphine hydrochloride; naloxone hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Buprenorphine Hydrochloride And Naloxone Hydrochloride
A generic version of BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE was approved as buprenorphine hydrochloride; naloxone hydrochloride by ACTAVIS ELIZABETH on February 22nd, 2013.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE?
- What are the global sales for BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE?
- What is Average Wholesale Price for BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE?
Summary for BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE
| US Patents: | 0 |
| Applicants: | 15 |
| NDAs: | 18 |
| Finished Product Suppliers / Packagers: | 22 |
| Raw Ingredient (Bulk) Api Vendors: | 4 |
| Clinical Trials: | 134 |
| Patent Applications: | 279 |
| DailyMed Link: | BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE at DailyMed |
Recent Clinical Trials for BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Johns Hopkins University | Phase 3 |
| Cure Addiction Now | Phase 3 |
| Bicycle Health | Phase 4 |
See all BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE clinical trials
Pharmacology for BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE
| Drug Class | Opioid Antagonist Partial Opioid Agonist |
| Mechanism of Action | Opioid Antagonists Partial Opioid Agonists |
US Patents and Regulatory Information for BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Specgx Llc | BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE | buprenorphine hydrochloride; naloxone hydrochloride | TABLET;SUBLINGUAL | 207000-002 | Dec 13, 2017 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Lannett Co Inc | BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE | buprenorphine hydrochloride; naloxone hydrochloride | TABLET;SUBLINGUAL | 205022-002 | Sep 19, 2016 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Sun Pharm | BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE | buprenorphine hydrochloride; naloxone hydrochloride | TABLET;SUBLINGUAL | 201633-001 | Aug 5, 2016 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
